new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)


Similar
Filing Names

Incyte Corporation
Incyte Corporation A Delaware Corporation
Incyte Corporationn A Delaware Corporation

Popular
Companies


Web
Adobe patents
Amazon patents
Apple patents
Ebay patents
Facebook patents
Google patents
IBM patents
Linkedin patents
Microsoft patents
Oracle patents
Red Hat patents
Yahoo patents

Food/Health
Adidas
Nike patents
Pfizer patents
Monsanto patents
Medtronic patents
Kraft patents

Transportation
Boeing patents
Tesla Motors patents

Telecom
Qualcomm patents
Motorola patents
Nokia patents
RIMM patents

Industrial/Electronics
AMD
Applied Materials
Seagate patents
General Electric
Caterpillar patents
Samsung
Wal-mart patents

  

Incyte Corporation patents


      
Recent patent applications related to Incyte Corporation. Incyte Corporation is listed as an Agent/Assignee. Note: Incyte Corporation may have other listings under different names/spellings. We're not affiliated with Incyte Corporation, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Incyte Corporation-related inventors




Search recent Press Releases: Incyte Corporation-related press releases
Count Application # Date Incyte Corporation patents (updated weekly) - BOOKMARK this page
12010002252201/28/10 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
22016016814806/16/16 Tricyclic heterocycles as bet protein inhibitors
32016015981706/09/16 Tricyclic heterocycles as bet protein inhibitors
42016013762605/19/16 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
52016013765005/19/16 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
62016013033205/12/16 Antibodies to human signal peptide-containing proteins
72016011516404/28/16 Bicyclic heterocycles as fgfr4 inhibitors
82016007572103/17/16 Tricyclic heterocycles as bet protein inhibitors
92016006725303/10/16 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
102016004665002/18/16 Tricyclic heterocycles as bet protein inhibitors
112016002268501/28/16 Heterocyclylamines as pi3k inhibitors
122016002410901/28/16 Tricyclic fused thiophene derivatives as jak inhibitors
132016002411701/28/16 Heterocyclylamines as pi3k inhibitors
142016001569501/21/16 Tricyclic fused thiophene derivatives as jak inhibitors
152016000971101/14/16 Triazolopyridines and triazolopyrazines as lsd1 inhibitors
162016000971201/14/16 Imidazopyridines and imidazopyrazines as lsd1 inhibitors
172016000971401/14/16 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
182016000972001/14/16 Imidazopyrazines as lsd1 inhibitors
192016000972101/14/16 Triazolopyridines and triazolopyrazines as lsd1 inhibitors
202016000972601/14/16 Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
212016000079501/07/16 Treatment of b-cell malignancies by a combination jak and pi3k inhibitors
222015036109412/17/15 Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
232015034295212/03/15 Treatment of chronic neutrophilic leukemia (cnl) and atypical chronic myeloid leukemia (acml) by inhibitors of jak1
242015034449712/03/15 Processes of preparing a jak1 inhibitor and new forms thereto
252015032953411/19/15 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
262015032956111/19/15 Amido compounds and their use as pharmaceuticals
272015031518511/05/15 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
282015030749310/29/15 1h-pyrrolo[2,3-c]pyridin-7(6h)-ones and pyrazolo[3,4-c]pyridin-7(6h)-ones as inhibitors of bet proteins
292015029170110/15/15 Methods for treating disorders associated with human signal peptide-containing molecules
302015028439010/08/15 N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors
312015025079009/10/15 Topical formulation for a jak inhibitor
322015024604609/03/15 Jak1 inhibitors for the treatment of myelodysplastic syndromes
332015023849208/27/15 Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
342015022537508/13/15 Cyclopropylamines as lsd1 inhibitors
352015022537908/13/15 Cyclopropylamines as lsd1 inhibitors
362015022539408/13/15 Cyclopropylamines as lsd1 inhibitors
372015022540108/13/15 Cyclopropylamines as lsd1 inhibitors
382015022541108/13/15 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
392015021817408/06/15 Processes for preparing jak inhibitors and related intermediate compounds
402015021069207/30/15 Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
412015019037807/09/15 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3- dioxygenase
422015018380507/02/15 Processes and intermediates for making a jak inhibitor
432015017560406/25/15 Tricyclic heterocycles as bet protein inhibitors
442015016490006/18/15 Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
452015014834205/28/15 Bicyclic heterocycles as bet protein inhibitors
462015014834805/28/15 Salts of 2-fluoro-n-methyl-4-[7-(quinolin-6-yl-methyl)- imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
472015014837205/28/15 Bicyclic heterocycles as bet protein inhibitors
482015014837505/28/15 Bicyclic heterocycles as bet protein inhibitors
492015013367405/14/15 Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor
502015008763203/26/15 Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidines derivatives as jak inhibitors
512015008766203/26/15 Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
522015006544703/05/15 Survival benefit in patients with solid tumors with elevated c-reactive protein levels
532015006548403/05/15 Sustained release dosage forms for a jak1 inhibitor
542015005726502/26/15 Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
552015002505601/22/15 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
562015001717301/15/15 Antibodies to human transmembrane proteins
572015001154001/08/15 Tricyclic heterocycles as bet protein inhibitors
582015000416501/01/15 Secreted proteins
592014037729212/25/14 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
602014037840012/25/14 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
612014037121612/18/14 Purinone derivatives as hm74a agonists
622014034303011/20/14 Bipyrazole derivatives as jak inhibitors
632014031596210/23/14 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3- dioxygenase
642014027503009/18/14 Tricyclic heterocycles as bet protein inhibitors
652014027503109/18/14 Piperidin-4-yl azetidine derivatives as jak1 inhibitors
662014027512709/18/14 Substituted heteroaryl fused derivatives as pi3k inhibitors
672014025694109/11/14 Processes and intermediates for making a jak inhibitor
682014024913209/04/14 Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
692014024208608/28/14 Polynucleotides encoding signal peptide-containing molecules
702014024330808/28/14 Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
712014024336008/28/14 Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
722014022727508/14/14 Methods of treating and diagnosing pancreatitis
732014022727808/14/14 Antibodies to human signal peptide-containing proteins
742014022834608/14/14 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
752014022137908/07/14 N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
762014020021607/17/14 Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
772014020022707/17/14 Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
782014018753007/03/14 Aza spiro alkane derivatives as inhibitors of metalloproteases
792014017140506/19/14 Fused pyrazoles as fgfr inhibitors
802014017140906/19/14 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
812014015528806/05/14 Methods for diagnosing cancer
822014015537706/05/14 3-cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
832014015540406/05/14 Piperazinylpiperidine derivatives as chemokine receptor antagonists
842014013535005/15/14 Sustained-release dosage forms of ruxolitinib
852014012119805/01/14 Tricyclic fused thiophene derivatives as jak inhibitors
862014012122205/01/14 Pyrimidinones as pi3k inhibitors
872014006644803/06/14 Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors
882014005690602/27/14 Secreted proteins
892014005791202/27/14 Pyrimidine-4,6-diamine derivatives as pi3k inhibitors
902014004581402/13/14 Pyrazine derivatives as fgfr inhibitors
912014003134401/30/14 Azepine inhibitors of janus kinases
922014002366301/23/14 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
932014001837401/16/14 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
942014000516601/02/14 Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
952014000521001/02/14 Heteroaryl substituted pyrrolo[2,3-b] pyridines and pyrrolo[2,3-b] pyrimidines as janus kinase inhibitors
962013034515712/26/13 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
972013034522412/26/13 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
982013032451512/05/13 Imidazotriazines and imidazopyrimidines as kinase inhibitors
992013025319009/26/13 Processes for preparing jak inhibitors and related intermediate compounds
1002013025319109/26/13 Processes for preparing jak inhibitors and related intermediate compounds
1012013025319309/26/13 Processes for preparing jak inhibitors and related intermediate compounds
1022013024378109/19/13 Signal peptide-containing proteins
1032013024492709/19/13 Polynucleotides encoding signal peptide-containing molecules
1042013024499909/19/13 Substituted heterocyclic compounds
1052013022476908/29/13 Methods of using chemokine panec-1 antibodies
1062013022555608/29/13 Azetidine and cyclobutane derivatives as jak inhibitors
1072013019025007/25/13 Polynucleotides encoding human signal peptide-containing proteins
1082013017759007/11/13 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1092013013768105/30/13 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1102013012324605/16/13 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
1112013011623005/09/13 3-aminopyrrolidine derivatives as modulators of chemokine receptors
1122013009614404/18/13 Isoindolinone and pyrrolopyridinone derivatives as akt inhibitors
1132013005894203/07/13 Human beta-adrenergic receptor kinase polypeptide and methods
1142013005983503/07/13 Heterocyclylamines as pi3k inhibitors
1152013006002603/07/13 Processes and intermediates for making a jak inhibitor
1162013004596302/21/13 Cyclohexyl azetidine derivatives as jak inhibitors
1172013001803401/17/13 Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
1182013001806801/17/13 Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1
1192012032978212/27/12 Azepine inhibitors of janus kinases
1202012030146411/29/12 Janus kinase inhibitors for treatment of dry eye and other eye related diseases
1212012029591211/22/12 Piperazinylpiperidine derivatives as chemokine receptor antagonists
1222012027080910/25/12 Human transmembrane proteins
1232012012285805/17/12 Lactam compounds and their use as pharmaceuticals
1242012004096402/16/12 N-substituted piperidines and their use as pharmaceuticals
1252012003517202/09/12 Purinone derivatives as hm74a agonists
1262012001493701/19/12 Human beta-adrenergic receptor kinase polypeptide and methods
1272012001592801/19/12 Amido compounds and their use as pharmaceuticals
1282011025121510/13/11 Macrocyclic compounds and their use as kinase inhibitors
1292011021296709/01/11 Imidazo[1,2-b][1,2,4]triazines as c-met inhibitors
1302011020775408/25/11 Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors
1312011013678106/09/11 Imidazotriazines and imidazopyrimidines as kinase inhibitors
1322011008681004/14/11 Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d] pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
1332011008215904/07/11 Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
1342011005321703/03/11 Polynucleotides encoding signal peptide-containing molecules
1352010027933311/04/10 Methods of treatment with antibodies to a chemokine expressed in inflamed adenoid
1362010025611410/07/10 Amido compounds and their use as pharmaceuticals
1372010024067109/23/10 Substituted heterocyclic compounds
1382010020303908/12/10 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
1392010019080407/29/10 Macrocyclic compounds and their use as kinase inhibitors
1402010017390107/08/10 Substituted heterocyclic compounds
1412010013740106/03/10 2-methylprop anamides and their use as pharmaceuticals
1422010011950305/13/10 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
1432010009961704/22/10 Secreted proteins
1442009031840512/24/09 4-pyrazolyl-n-arylpyrimidin-2-amines and 4-pyrazolyl-n-heteroarylpyrimidin-2-amines as janus kinase inhibitors
1452009029194611/26/09 Lactam compounds and their use as pharmaceuticals
1462009028677411/19/09 Purinone derivatives as hm74a agonists
1472009028677811/19/09 Macrocyclic compounds and their use as kinase inhibitors
1482009027468011/05/09 Human phospholipases
1492009023390309/17/09 Azetidine and cyclobutane derivatives as jak inhibitors
1502009021576608/27/09 Tetracyclic inhibitors of janus kinases
1512009019788708/06/09 Piperazinylpiperidine derivatives as chemokine receptor antagonists
1522009018195907/16/09 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1532009012464905/14/09 Aza spiro alkane derivatives as inhibitors of metalloproteases
1542009008844604/02/09 Purinone derivatives as hm74a agonists
1552009007626903/19/09 Purinone derivatives as hm74a agonists
1562012026367610/18/12 Compositions, methods and kits relating to her-2 cleavage
1572012005807903/08/12 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
1582012001498901/19/12 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
1592011031147912/22/11 Modulators of indoleamine 2,3-dioxygenase and methods of using the same
1602011022321009/15/11 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1612011022415709/15/11 Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
1622011017227907/14/11 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1632011016518807/07/11 N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
1642011008683504/14/11 Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-5-yl-amines as janus kinase inhibitors
1652009029880812/03/09 Inhibitors of 11-beta hydroxyl steroid dehydrogenase type i and methods of using the same
1662009019786908/06/09 Azepine inhibitors of janus kinases



ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Incyte Corporation in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Incyte Corporation with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###